Land: Ástralía
Tungumál: enska
Heimild: Department of Health (Therapeutic Goods Administration)
carbidopa monohydrate, Quantity: 27 mg (Equivalent: carbidopa, Qty 25 mg); levodopa, Quantity: 100 mg
Arrotex Pharmaceuticals Pty Ltd
Tablet, uncoated
Excipient Ingredients: magnesium stearate; quinoline yellow aluminium lake; crospovidone; microcrystalline cellulose; pregelatinised maize starch
Oral
100 tablets, 10 tablets, 20 tablets
(S4) Prescription Only Medicine
LEVODOPA/CARBIDOPA GPPL is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. LEVODOPA/CARBIDOPA GPPL frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.
Visual Identification: Round, light yellow uncoated tablets with 'C' on one side and '19' on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2018-01-11